Sundar S, Makharia A, More D K, Agrawal G, Voss A, Fischer C, Bachmann P, Murray H W
The Kala-Azar Medical Research Center, Banaras Hindu University Institute of Medical Sciences, Varanasi, India.
Clin Infect Dis. 2000 Oct;31(4):1110-3. doi: 10.1086/318122.
A total of 54 Indian patients with visceral leishmaniasis were treated with oral miltefosine, 50 mg given twice daily, for 14 days (18 patients; group A), 21 days (18; group B), or 28 days (18; group C). Cure was achieved in 89% of group A, 100% of group B, and 100% of group C. Adverse reactions were self-limited and primarily mild. The 21-day miltefosine regimen combines high-level efficacy, convenient dosing, and a relatively short duration.
共有54名印度内脏利什曼病患者接受了口服米替福新治疗，剂量为每日两次，每次50毫克，疗程分别为14天（18名患者；A组）、21天（18名；B组）或28天（18名；C组）。A组的治愈率为89%，B组为100%，C组为100%。不良反应为自限性，主要为轻度。21天的米替福新治疗方案疗效高、给药方便且疗程相对较短。
